SCHEMBL2453630

SCHEMBL2453630

CCSc1ccccc1/C(=N\N(C)C)n1ccnc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 6/20 0.48
ALDH1A1 P00352 3/20 0.40
MAPK1 P28482 3/20 0.39
MITF O75030 1/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36
HPGD P15428 5/20 0.36
TDP1 Q9NUW8 1/20 0.36
NR1I2 O75469 1/20 0.34
NR3C1 P04150 1/20 0.34
HTR1A P08908 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
CNR1 P21554 1/20 0.34
TBXA2R P21731 1/20 0.34
SLC6A2 P23975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2453633 1.00 HSD17B10 (0.48) HSD17B10ALDH1A1MAPK1MITFLMNA
SCHEMBL2446737 0.91 HSD17B10 (0.40) HSD17B10ALDH1A1MAPK1MITFLMNA
SCHEMBL2446733 0.91 HSD17B10 (0.40) HSD17B10ALDH1A1MAPK1MITFLMNA
SCHEMBL2456042 0.89 HSD17B10 (0.41) HSD17B10ALDH1A1LMNANPSR1ADRB2
SCHEMBL2456044 0.89 HSD17B10 (0.41) HSD17B10ALDH1A1LMNANPSR1ADRB2
SCHEMBL2449495 0.88 HSD17B10 (0.40) HSD17B10ALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2449496 0.88 HSD17B10 (0.40) HSD17B10ALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2453104 0.86 ALDH1A1 (0.38) HSD17B10ALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2453101 0.86 ALDH1A1 (0.38) HSD17B10ALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2451510 0.86 KMT2A (0.40) HSD17B10ALDH1A1LMNATSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022072-B2 Azolylmethylidenehydrazine derivative and use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2011-09-20 US claimed
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-07-29 US claimed
US-8022072-B2 Azolylmethylidenehydrazine derivative and use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2011-09-20 US disclosed
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-07-29 US disclosed
EP-2168951-A1 AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF ARSA, AHR, HRH2 HSD17B10 1569/4885ALDH1A1 831/4885MAPK1 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.